Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Oncoimmunology. 2012 Sep 1;1(6):959-961. doi: 10.4161/onci.20368.


Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more effective.